CJC-1295 + Ipamorelin Stack: The Complete Protocol Guide

Why Combine CJC-1295 and Ipamorelin?

Growth hormone release is regulated by two competing signal pathways:

• GHRH (growth hormone-releasing hormone): Produced in the hypothalamus, stimulates the pituitary to release GH. CJC-1295 is a synthetic GHRH analog — it mimics this signal.
• Ghrelin / GHS-R pathway: A separate receptor system that also stimulates GH release and synergizes with GHRH. Ipamorelin activates this pathway.

When you activate both pathways simultaneously, the pituitary's GH output is amplified significantly — studies show the combination produces 2–5x more GH than either peptide alone. This is not additive; it's synergistic, because the two pathways potentiate each other at the pituitary level.

Ipamorelin is selected specifically because it's the cleanest GHRP: unlike GHRP-2 and GHRP-6, ipamorelin doesn't significantly raise cortisol or prolactin, which would counteract some of GH's benefits. The result is selective GH stimulation with a physiologically normal pulsatile pattern.

Dosing Protocol

Which CJC-1295 form to use:

• No DAC (most common): Short-acting, mimics natural GHRH pulsatility. Peaks and clears within 30 minutes — keeps GH release in a physiological pattern. Best for general anti-aging, sleep, and body composition.
• With DAC: The Drug Affinity Complex extends half-life to 6–8 days, producing sustained GH elevation rather than pulsatile spikes. Better for maximizing IGF-1 and lean mass gains; less physiological. Used less frequently because of the blunted pulsatility.

Bedtime dosing rationale: GH is predominantly released during slow-wave sleep (SWS). Timing the peptide injection to coincide with sleep onset amplifies the natural nocturnal GH pulse rather than creating an out-of-pattern spike. Fast 2–3 hours before injection — food (especially carbohydrates) raises insulin, which suppresses GH release and blunts the peptide's effect.

What to Expect: Results Timeline

Results are gradual and physiological — this is not like anabolic steroids or exogenous HGH. The stack works by optimizing your body's own GH axis, not overriding it. Expect incremental improvements, not dramatic transformation.

Monitoring and Cycle Structure

Lab monitoring: Check IGF-1 at baseline and at 6–8 weeks. Target: upper third of age-appropriate reference range. If IGF-1 is already high-normal, the stack may not add much benefit. Also monitor fasting glucose — GH is insulin-antagonizing, and some individuals see glucose elevation.

Cycle length: Most protocols run 3–6 months on, followed by 4–8 weeks off. The off period prevents downregulation of pituitary sensitivity to the peptides. There's no firm consensus on cycle length — some physicians run continuous protocols at lower doses; others prefer cycling.

Who benefits most: Adults over 30 experiencing age-related GH decline (somatopause), athletes and active individuals focused on recovery and body composition, and anyone with poor sleep quality as a primary concern. The stack is less useful for people who already have optimal IGF-1 levels.